Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Nvidia rebounds 4% after earnings 🔼 Can the AI giant lift Wall Street?
Shares of Nike drop despite business turnaround 🚩Disney and Home Depot after earnings reports
US Open: Wall Street on Edge Ahead of Nvidia Earnings 🚩 Could Rising Oil Prices Weigh on Stocks?
Nvidia Preview: Strong Results, Uncertain Future